Reduced hepatic extraction of palmitate in steatosis correlated to lower level of liver fatty acid binding protein


Autoria(s): Hung, Daniel Y.; Siebert, Gerhard A.; Chang, Ping; Burczynski, Frank J.; Roberts, Michael S.
Contribuinte(s)

M. Montrose

B. B. Rauner

Data(s)

01/01/2005

Resumo

Nonalcoholic fatty liver disease is the most common of all liver diseases. The hepatic disposition [H-3]palmitate and its low-molecular-weight metabolites in perfused normal and steatotic rat liver were studied using the multiple indicator dilution technique and a physiologically based slow diffusion/bound pharmacokinetic model. The steatotic rat model was established by administration of 17alpha-ethynylestradiol to female Wistar rats. Serum biochemistry markers and histology of treated and normal animals were assessed and indicated the presence of steatosis in the treatment group. The steatotic group showed a significantly higher alanine aminotransferase-to-aspartate aminotransferase ratio, lower levels of liver fatty acid binding protein and cytochrome P-450, as well as microvesicular steatosis with an enlargement of sinusoidal space. Hepatic extraction for unchanged [H-3]palmitate and production of low-molecular-weight metabolites were found to be significantly decreased in steatotic animals. Pharmacokinetic analysis suggested that the reduced extraction and sequestration for palmitate and its metabolites was mainly attributed to a reduction in liver fatty acid binding protein in steatosis.

Identificador

http://espace.library.uq.edu.au/view/UQ:75135

Idioma(s)

eng

Publicador

American Physiological Society

Palavras-Chave #Gastroenterology & Hepatology #Physiology #17 Alpha-ethynylestradiol #Hepatic Palmitate Disposition #Residence Time Distributions #Nonalcoholic Steatohepatitis #Cryptogenic Cirrhosis #Rat #Model #Transport #Disease #Albumin #Chain #Hepatocytes #C1 #320503 Clinical Pharmacology and Therapeutics #730118 Organs, diseases and abnormal conditions not elsewhere classified
Tipo

Journal Article